• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
PF-04691502 Dihydrate

PF-04691502 Dihydrate

Product ID P2002
Cas No.
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $136.70 In stock
5 mg $246.10 In stock
10 mg $392.10 Please Inquire
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

PF-04691502 inhibits PI3K and mTORC1/2, exhibiting anticancer chemotherapeutic and anti-angiogenic activities. In nasopharyngeal carcinoma cells, PF-04691502 induces G0/G1 cell cycle arrest and apoptosis, inhibiting proliferation. In similar animal models, PF-04691502 decreases tumor volume and weight. Additionally, PF-04691502 decreases tumor growth of bladder cancer tumors in vivo and decreases VEGF secretion and cell proliferation in vitro.

Product Info

Purity

≥98%

Formula

C22H27N5O4 • 2H2O

Formula Wt.

461.51

Solubility

DMSO 14 mg/mL (32.9 mM) Water Insoluble Ethanol Insoluble

Appearance

Yellow Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

P2002 MSDS PDF

Info Sheet

P2002 Info Sheet PDF

Brochures

PI3K-Akt-mTORC Pathway Booklet

References

Cirone P, Andresen CJ, Eswaraka JR, et al. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemother Pharmacol. 2014 Mar;73(3):525-38. PMID: 24442130.

Wong CH, Loong HH, Hui CW, et al. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. Invest New Drugs. 2013 Dec;31(6):1399-408. PMID: 23975511.

Yuan J, Mehta PP, Yin MJ, et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011 Nov;10(11):2189-99. PMID: 21750219.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • O4533

    Oligomycin

    Mixture of oligomycins A, B, C; oxidative phosp...

    ≥97%
  • V0147

    Valproic Acid Sodium

    T-type Ca2+ and voltage-gated Na+ channel block...

    ≥98%
  • L0226

    Lagochiline

    Diterpene alkaloid found in Lagochilus.

    ≥98%
  • D324094

    Diclofenac Related Compound A

    Impurity of diclofenac

    ≥98%
  • A761003

    AT-7519 Hydrochloride

    ATP competitive CDK inhibitor.

    ≥98%
  • A8812

    AWD 131-138

    GABA-A positive modulator.

    ≥99%
  • M1579

    Methazolamide

    Carbonic anhydrase inhibitor.

    ≥98%
  • S8245

    Sulfadiazine

    Sulfonamide; folate production inhibitor.

    ≥98%
  • A990144

    AZD4320

    Inhibitor of Bcl-2 and Bcl-xL

    ≥99%
  • R1724

    Regadenoson

    Adenosine A2A agonist.

    ≥99%
  • H5654

    Honokiol

    Lignan found in species of Magnolia; GABA-A pot...

    ≥99%
  • D183740

    Desoxypipradrol

    NDRI inhibitor

    ≥98%
  • S8169

    Suramin Hexasodium

    RyR agonist, SIRT, telomerase, P2Y, GPCR inhibi...

    ≥98%
  • H1673

    Hesperidin

    Flavonoid found in species of Citrus; COX-2 inh...

    ≥95%
  • T3461

    Tiplaxtinin

    PAI-1 inhibitor.

    ≥98%
  • D3302

    Diaveridine Hydrochloride

    Coccidiostat; dihydrofolate reductase inhibitor...

    ≥98%
  • B1746

    Belinostat

    HDAC inhibitor.

    ≥98%
  • S7871

    Stresscopin, human

    Peptide, urocortin III analog; CRFR2 agonist.

    ≥95%
  • V3479

    Vitamin K3

    Synthetic analog of 1,4-naphthoquinone, precurs...

    ≥98%
  • V1668

    Vemurafenib

    B-Raf inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only